
Golden Retriever Puppy Wants To Look at Cat Sibling but There's a Problem
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A golden retriever puppy named Teddy, from New Zealand, has captured the hearts of social media users after his owner revealed the reason why he can't look directly at his feline sister.
In a viral TikTok video shared on Friday under the username @teddy_the_golden__, the puppy can be seen cautiously glancing at the kitty, and quickly turning his head around once he realizes she's staring him down.
"When you can't even make eye contact with your sister [because] she will punch you in the face," reads the caption.
While dogs are usually much bigger than their feline counterparts, it's actually not uncommon for them to petrified of cats. This is due to a mix of instincts, past experiences, and the felines' powerful personalities, according to Canada Vet.
A dog, who for example, experienced cats' claws or bites as a puppy, may still remember the way it felt, which can in turn cause them to be fearful. Some particular dog breeds, including smaller ones, or those bred for companionship, are more likely to be afraid of cats.
Dogs are easily scared of cats, but what are cats scared of? Cats are often afraid of loud noises, strangers, water, changes in their environment, humans, veterinarians, confined spaces, dogs sometimes, and even cucumbers, according to Pet MD.
While cucumbers may sound like an unreasonable fear, scientists believe that it's not the cucumber itself that cats are afraid of, but rather the fact that it's an unknown object that they have never seen and do not understand.
In most cases, cats and dogs can live together without any issues, and can even become best of friends! A 2020 study by Italian scientists, published in the journal PLOS ONE, found that over 64 percent of cats and dogs living together also played together; 58 percent chased each other; and 41 percent fought.
A stock image shows a cat staring a golden retriever down as they lay side by side on a rug on the floor.
A stock image shows a cat staring a golden retriever down as they lay side by side on a rug on the floor.
getty images
The video quickly went viral on TikTok and it has so far received over 283,000 views and 37,100 likes on the platform.
One user, Lifecoachph1, commented: "My American bully is scared of his cat boss sister just like this."
KM said: "This older sister-younger brother dynamic spans across all species I'm afraid."
The Essential wrote: "Ok. I see nothing in here mom—but actually crying for help 'momma did you see that,' such a best moment."
Newsweek reached out to @teddy_the_golden__ for comment via TikTok comments. We could not verify the details of the case.
Do you have funny and adorable videos or pictures of your pet you want to share? Send them to life@newsweek.com with some details about your best friend and they could appear in our Pet of the Week lineup.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Newsweek
2 hours ago
- Newsweek
Florida Weatherman Issues DOGE Cuts Warning During TV Forecast
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Florida weatherman John Morales decried the federal spending cuts to the National Weather Service and NOAA during his forecast on NBC6 on Monday, saying it is affecting his ability to do his job. Morales played a clip of him confidently saying that Hurricane Dorian was going to turn away from Florida a few years earlier, seeking to reassure the state's residents. "And I am here to tell you, that I am not sure I can do that this year, because of the cuts, the gutting, the sledgehammer attack on science in general," Morales said. He described some of the forecasting-related impacts that the cuts recommended by the Department of Government Efficiency (DOGE) have had, including substantially fewer staff at key agencies and a reduction in weather balloons. "And what we're starting to see is that the quality of the forecast is becoming degraded," Morales said. "There's also a chance, because of some of these cuts, that NOAA hurricane hunter aircraft will not be able to fly this year, and with less reconnaissance missions, we may be flying blind, and we may not exactly know how strong a hurricane is before it reaches the coastline, like happened a couple of years ago in Hurricane Otis in Acapulco, Mexico. "So I was asked to talk about this today. I'm glad I was. I just want you to know that what you need to do is call your representatives, and make sure that these cuts are stopped." South Florida weatherman tells viewers he can't accurately predict hurricanes because of government cuts — 🌊 R Saddler (@Politics_PR) June 4, 2025 This is a developing article. Updates to follow.


Business Wire
5 hours ago
- Business Wire
ALIKO SCIENTIFIC (Ikonisys SA), Through Its Fully Owned Italian Subsidiary Hospitex International, Signs Exclusive Distribution Agreement for Italy with Menarini Diagnostics
FLORENCE, Italy & PARIS--(BUSINESS WIRE)--Regulatory News: ALIKO SCIENTIFIC (Ikonisys SA) Euronext Growth: ALIKO, through its fully owned Italian subsidiary Hospitex International is pleased to announce the signing of an exclusive distribution agreement with Menarini Diagnostics, the European largest distributor in the field of pathology and IVD (in vitro diagnostics). Under the terms of the agreement, Menarini Diagnostics will exclusively distribute, in the Italian market, ALIKO SCIENTIFIC group's product portfolio that includes FISH technology (manufactured in the USA by Ikonisys) and Hospitex's full range of cytology, cell-blocking and rapid immunohistochemistry products. Menarini Diagnostics Italy, part of Menarini pharmaceutical group, is the European largest IVD distribution player, with a track record and extensive experience in pathology. The company already distributes products from leading global manufacturers in the sector. The addition of the ALIKO SCIENTIFIC business lines will further enhance Menarini's offering, complementing its current histology solutions for anatomical pathology laboratories and thus achieving one of the most comprehensive and integrated offers in the market. Hospitex has estimated the addressable Italian market for cytology and cell block product lines at approximately €28 million annually. Market forecasts for the FISH and immunohistochemistry segments will be developed following market entry and the collection of relevant data. The Group's goal is to capture a significant share of the market within the first three years of commercial rollout. Francesco Trisolini, CEO of Hospitex, commented: "This agreement with Menarini Diagnostics represents a major milestone for the Group. By partnering with the largest European IVD distributor, we are confident that our innovative solutions will reach a broader market and significantly improve diagnostic capabilities in pathological anatomy. This agreement will also fuel our R&D programs to release new breakthrough solutions for the cancer diagnostics market, such as FISH probes in a short timeframe." Fabio Piazzalunga, Global Head of Diagnostics and General Manager of Menarini Diagnostics, added: "At Menarini, we are deeply committed to advancing oncology diagnostics, and the addition of ALIKO SCIENTIFIC's cutting-edge technology to our portfolio aligns perfectly with our strategic vision. This collaboration will allow us to offer a more comprehensive suite of solutions to pathology professionals across Italy." About ALIKO SCIENTIFIC (Ikonisys SA) Headquartered in Paris, ALIKO SCIENTIFIC is the parent company of an international ecosystem of businesses dedicated to advancing oncology diagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the company coordinates industrial, financial and research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO SCIENTIFIC's mission is to innovate cancer diagnosis by uniting cutting-edge technologies, resources, and strategic investments to create a global center of excellence in oncology. For more information, visit: About IKONISYS Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell (CTC) detection. Leveraging advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys provides unmatched precision, scalability, and efficiency in cancer diagnostics and treatment monitoring. Recognized as pioneer in automation for rare cell detection, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted therapies and improve patient outcomes. For more information, visit: About HOSPITEX Hospitex, based in Florence, Italy, is a global leader in cytology innovation. The company conducts in-house research, development, and production, thus ensuring the highest standards of quality. Hospitex offers the world's most advanced Liquid-Based Cytology (LBC) technology, capable of processing any cytological sample with unmatched precision. Hospitex is uniquely positioned as the only company fully prepared for seamless digital integration, paving the way for a transformative future in cytology diagnostics. For more information, visit: Disclaimer This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.

Yahoo
5 hours ago
- Yahoo
ALIKO SCIENTIFIC (Ikonisys SA), Through Its Fully Owned Italian Subsidiary Hospitex International, Signs Exclusive Distribution Agreement for Italy with Menarini Diagnostics
FLORENCE, Italy & PARIS, June 04, 2025--(BUSINESS WIRE)--Regulatory News: ALIKO SCIENTIFIC (Ikonisys SA) Euronext Growth: ALIKO, through its fully owned Italian subsidiary Hospitex International is pleased to announce the signing of an exclusive distribution agreement with Menarini Diagnostics, the European largest distributor in the field of pathology and IVD (in vitro diagnostics). Under the terms of the agreement, Menarini Diagnostics will exclusively distribute, in the Italian market, ALIKO SCIENTIFIC group's product portfolio that includes FISH technology (manufactured in the USA by Ikonisys) and Hospitex's full range of cytology, cell-blocking and rapid immunohistochemistry products. Menarini Diagnostics Italy, part of Menarini pharmaceutical group, is the European largest IVD distribution player, with a track record and extensive experience in pathology. The company already distributes products from leading global manufacturers in the sector. The addition of the ALIKO SCIENTIFIC business lines will further enhance Menarini's offering, complementing its current histology solutions for anatomical pathology laboratories and thus achieving one of the most comprehensive and integrated offers in the market. Hospitex has estimated the addressable Italian market for cytology and cell block product lines at approximately €28 million annually. Market forecasts for the FISH and immunohistochemistry segments will be developed following market entry and the collection of relevant data. The Group's goal is to capture a significant share of the market within the first three years of commercial rollout. Francesco Trisolini, CEO of Hospitex, commented: "This agreement with Menarini Diagnostics represents a major milestone for the Group. By partnering with the largest European IVD distributor, we are confident that our innovative solutions will reach a broader market and significantly improve diagnostic capabilities in pathological anatomy. This agreement will also fuel our R&D programs to release new breakthrough solutions for the cancer diagnostics market, such as FISH probes in a short timeframe." Fabio Piazzalunga, Global Head of Diagnostics and General Manager of Menarini Diagnostics, added: "At Menarini, we are deeply committed to advancing oncology diagnostics, and the addition of ALIKO SCIENTIFIC's cutting-edge technology to our portfolio aligns perfectly with our strategic vision. This collaboration will allow us to offer a more comprehensive suite of solutions to pathology professionals across Italy." About ALIKO SCIENTIFIC (Ikonisys SA) Headquartered in Paris, ALIKO SCIENTIFIC is the parent company of an international ecosystem of businesses dedicated to advancing oncology diagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the company coordinates industrial, financial and research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO SCIENTIFIC's mission is to innovate cancer diagnosis by uniting cutting-edge technologies, resources, and strategic investments to create a global center of excellence in oncology. For more information, visit: About IKONISYS Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell (CTC) detection. Leveraging advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys provides unmatched precision, scalability, and efficiency in cancer diagnostics and treatment monitoring. Recognized as pioneer in automation for rare cell detection, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted therapies and improve patient outcomes. For more information, visit: About HOSPITEX Hospitex, based in Florence, Italy, is a global leader in cytology innovation. The company conducts in-house research, development, and production, thus ensuring the highest standards of quality. Hospitex offers the world's most advanced Liquid-Based Cytology (LBC) technology, capable of processing any cytological sample with unmatched precision. Hospitex is uniquely positioned as the only company fully prepared for seamless digital integration, paving the way for a transformative future in cytology diagnostics. For more information, visit: Disclaimer This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results. View source version on Contacts Ikonisys Alessandro MauriCFOinvestors@ NewCap Louis-Victor Delouvrier/Aurélie ManavarereInvestor Relationsikonisys@ Tel.: +33 (0)1 44 71 94 94 NewCap Arthur RouilléMedia Relationsikonisys@ Tel.: +33 (0)1 44 71 00 15